Characteristic | Value* | |
---|---|---|
Age (years, mean±SD, median) | 65±12, 65 | |
Gender (n, %) | ||
Male | 2966 | 97.6% |
Ethnicity (n, %) | ||
African-American | 414 | 13.6% |
Caucasian | 670 | 22.0% |
Hispanic | 44 | 1.45% |
Other | 341 | 11.2% |
Not documented | 1570 | 51.7% |
Baseline serum creatinine (mg/dL, mean±SD, median) | Mean±SD, Median | |
Overall (n=3039) | Overall: Overall: 1.28±0.86, 1.10 | |
Group 1: <1.5 mg/dL (n=2497) | Group 1: <1.5 mg/dL=1.05±0.19, 1.03 | |
Group 2: 1.5–2.0 mg/dL (n=377) | Group 2:1.5–2.0 mg/dL=1.67±0.16, 1.6 | |
Group 3: >2 mg/dL (n=165) | Group 3: >2 mg/dL=3.75±2.44, 2.7 | |
n | Per cent | |
Comorbidities | ||
Diabetes mellitus | 866 | 28.5 |
Hypertension | 1343 | 44.2 |
Chronic heart failure | 177 | 5.8 |
Coronary artery disease | 445 | 14.6 |
Gout | 69 | 2.3 |
SBP <100 mm Hg | 88 | 2.9 |
Concomitant use of: | ||
NSAIDs | 1053 | 34.6 |
Diuretics (total) | 1771 | 58.3 |
Loops | 773 | 25.4 |
Thiazides | 1264 | 41.6 |
K-sparing | 239 | 7.9 |
β-blockers | 1601 | 52.7 |
*Values are reported as mean±SD; median unless otherwise noted.
NSAIDs, non-steroidal anti-inflammatory drugs; SBH, systolic blood pressure.